What changed
2026-08-07 04:22 UTC → 2026-08-26 03:18 UTC ·
added
removed
Two recent market reports highlight accelerating growth in the The diagnostics sector. A sector continues to show strong growth projections across precision and point-of-care (PoC) segments. The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023 and US$145.53 billion in 2024, 2023, is projected expected to reach about approximately US$246.66 billion by 2029, reflecting maintaining an 11.1 % 11.1% compound annual growth rate. Drivers include This expansion is supported by AI and machine‑learning machine learning integration, expanding pharma‑diagnostics pharmaceutical collaborations, direct‑to‑consumer testing, wearable health monitors, and geographic expansion into emerging economies. A separate analysis of the U.S. point‑of‑care (PoC) diagnostics market shows it at US$9.45 billion in 2023, with an expected CAGR use of roughly 6.9 % through 2034. The broader global wearables for real-time monitoring. In the PoC sector, the global market is forecast to grow from US$328.7 billion in 2025 to US$604.3 billion by 2035 (≈7.3 % CAGR). Growth 2035. A more specific segment of the PoC testing market is fueled projected to reach US$48.88 billion by rising demand for rapid tests, multiplex and molecular platforms, IoT 2030, growing from US$31.46 billion in 2025 at a CAGR of approximately 9.5%. This growth is driven by a transition from centralized laboratories to bedside, clinic, and AI‑enabled connected devices, home-based diagnostics, alongside advancements in microfluidics, biosensors, and rapid imaging. Technological integration remains a shift toward decentralized, home‑based care. Leading firms central theme. The rise of AI-powered portable devices is notable, such as Royal Philips’ Compact 5000 series, an AI-enabled ultrasound system designed for automation and telemedicine. Additionally, increased pressure on centralized facilities is evident in regions like England, where the NHS reported a 4.8% increase in imaging examinations for the year ending March 2024. Major industry players, including Abbott, Thermo Fisher, Roche, Quest Diagnostics, and Siemens are investing Siemens, continue to invest heavily in next‑generation PoC these next-generation, decentralized technologies. Together, the reports illustrate a broader trend: both precision and point‑of‑care diagnostics are expected to expand rapidly over the next decade, driven by digital health innovations and changing care delivery models.